SDC1 and plasma cell myeloma: Since current clinical standard practice relies on flow cytometry and enrichment-based methods, the identification of malignant cells in myeloma remains a challenge, particularly in the blood of patients with a low population of CD138+ cells that can be isolated and characterized.